EIPA (hydrochloride)

EIPA (hydrochloride)

• CAS Number: 1345839-28-2
• UNSPSC Description: EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma[1][2][3][5].
• Target Antigen: Autophagy; COX; Na+/H+ Exchanger (NHE); Prostaglandin Receptor; TRP Channel
• Type: Reference compound
• Related Pathways: Autophagy;GPCR/G Protein;Immunology/Inflammation;Membrane Transporter/Ion Channel;Neuronal Signaling
• Applications: Neuroscience-Neuromodulation
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/eipa-hydrochloride.html
• Purity: 98.31
• Solubility: DMSO : 130 mg/mL (ultrasonic)
• Smiles: O=C(C1=NC(Cl)=C(N(CC)C(C)C)N=C1N)NC(N)=N.Cl
• Molecular Weight: 336.22
• References & Citations: [1]Dai XQ, et al. Inhibition of TRPP3 channel by MK-870 and analogs. Mol Pharmacol. 2007 Dec;72(6):1576-85.|[2]Shi H, et al. Na+/H+ Exchanger Regulates Amino Acid-Mediated Autophagy in Intestinal Epithelial Cells. Cell Physiol Biochem. 2017;42(6):2418-2429.|[3]Zhu BY, et al. A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis.Acta Biomater. 2023 Dec 18:S1742-7061(23)00724-9.|Emerg Microbes Infect. 2022 Dec;11(1):1135-1144.|J Nanobiotechnology. 2022 Jul 20;20(1):340.|Mol Pharm. 2021 Sep 7.|ACS Appl Mater Interfaces. 2020 Oct 14;12(41):45763-45771.|ACS Nano. 2020 Nov 24;14(11):14698-14714.|ACS Nano. 2024 Sep 11.|Adv Funct Mater. 2021 Apr 1.|Anal Chem. 2020 Jan 21;92(2):2103-2111.|Autophagy. 2022 Aug 1;1-19.|BBA-Gen Subjects. 2022: 130300.|Biol Open. 2023 Oct 5:bio.060081.|Biomacromolecules. 2021 Aug 12.|Biomaterials. 13 January 2022, 121373.|Bioorg Chem. 2022 Feb 12;121:105651.|bioRxiv. 2024 Jan 11.|Biotechnol J. 2022 Nov 2;e2200393|Carcinogenesis. 2024 Jul 15:bgae045.|Cell Metab. 2022 Dec 6;34(12):2018-2035.e8.|Chem Eng J. 2024 Sep 1.|Comput Struct Biotec. 2021;19:1933-1943.|Drug Deliv. 2021 Dec;28(1):800-813.|Exp Hematol. 2024 Oct 1:104651.|Genes Dev. 2021 Oct 1;35(19-20):1327-1332.|iScience. 2023 Mar 30.|J Biol Chem. 19 September 2022, 102511.|J Control Release. 2022 Oct 7;351:703-712.|J Control Release. 2023 Feb 17;355:675-684.|J Control Release. 2024 Apr 24:370:140-151.|J Exp Med. 2023 Mar 6;220(3):e20221316.|J Hazard Mater. 2021 Sep 5;417:126092.|J Nanobiotechnology. 2022 Jun 10;20(1):268.|J Neuroinflammation. 2024 May 10;21(1):125.|J Pathol. 2023 Jan 30. doi: 10.1002/path.6059.|J Virol. 2021 Sep 29;JVI0134521.|Matter. 2023 Aug 31.|Microvasc Res. 2021, 104219.|Nanotoxicology. 2023 Jan 26;1-18.|Nat Commun. 2024 Jan 2;15(1):162.|Nat Nanotechnol. 2024 Oct 28.|Pharmaceutics. 2020 Feb 17;12(2):167.|Pharmaceutics. 2024 Nov 21.|Sci Adv. 2020 Aug 12;6(33):eaaz1774.|Sci China Life Sci. 2021 May 27;1-21.|Sci China Mater. 63, 620-628 (2020).|Theranostics. 2022 Jan 1;12(3):1061-1073.|Vet Res. 2023 Mar 14;54(1):24.|Viruses. 2021 May 31;13(6):1035.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported